News - Novo Nordisk


Current filters:

Novo Nordisk

Popular Filters

100 to 124 of 130 results

FDA OKs pregnancy use of Novo Nordisk diabetes therapy Levemir


The US Food and Drug Administration has approved Levemir (insulin detemir [rDNA origin] injection), from…

DiabetesLevemirNorth AmericaNovo NordiskPharmaceuticalRegulation

Pfizer and Biocon cancel biosimilars deal


Indian biotech firm Biocon (BSE: 532523) and global drugs behemoth Pfizer (NYSE: PFE) yesterday announced…

Asia-PacificBioconBiotechnologyDiabetesInsulinLicensingNovo NordiskPfizerPharmaceutical

Victoza sales boost Novo Nordisk


Danish insulin giant Novo Nordisk (NVO: N) yesterday reported full-year 2011 sales of 66.35 billion Danish…

DiabetesFinancialNovo NordiskPharmaceuticalVictoza

Novo Nordisk opens type 1 diabetes R&D center in Seattle


Danish insulin giant Novo Nordisk (NVO: N) said this morning that it will establish a type 1 diabetes…

DiabetesNovo NordiskPharmaceuticalResearch

Lundbeck submits Selincro in EU; Novo Nordisk files Degludec in Japan


Danish CNS drug specialist Lundbeck (LUND: DC) revealed yesterday that it has submitted a marketing authorization…

Asia-PacificBiotie TherapiesDegludecDiabetesEuropeLundbeckNeurologicalNovo NordiskPharmaceuticalRegulationSelincro

Novo Nordisk reaches a milestone in stopping animal testing


Danish insulin giant Novo Nordisk (NVO: N) has released a video highlighting that, effective yesterday…

DiabetesNovo NordiskPharmaceuticalRegulationResearch

Denmark’s Novo Nordisk partners to tackle Qatar’s diabetes problem


According to Danish insulin giant Novo Nordisk (NVO: N) diabetes is on the rise in Qatar and poses a…

DiabetesHealthcareNovo NordiskPharmaceuticalRest of the World

GlaxoSmithKline’s albiglutide fails to show superiority over Novo Nordisk’s Victoza


UK pharma giant GlaxoSmithKline (LSE: GSK) released disappointing top-line results from the first of…

albiglutideDiabetesGlaxoSmithKlineNovo NordiskPharmaceuticalResearchVictoza

Novo Nordisk says DegludecPlus provides superior glycemic control vs Lantus


Denmark-based insulin giant Novo Nordisk (NVO: N) yesterday announced positive clinical results from…

DegludecDegludecPlusDiabetesLantusNovo NordiskPharmaceuticalResearchSanofi

EU OKs two new indications for Novo Nordisk’s Levemir


There was good news for Danish insulin giant Novo Nordisk (NVO: N) yesterday, when the European Commission…

DiabetesEuropeLevemirNovo NordiskPharmaceuticalRegulationVictoza

Modern insulins and Victoza drive 8% nine-month sales rise at Novo Nordisk


Danish insulin giant Novo Nordisk (NVO: N) has reported financial results for the first nine months of…

DiabetesFinancialNovo NordiskPharmaceutical

AstraZeneca to investment $200 million in Chinese manufacturing plant; Novo Nordisk debuts Victoza


Anglo-Swedish drug major AstraZeneca ILSE: AZN) said this morning that it is investing $200 million in…

Asia-PacificAstraZenecaDiabetesFinancialMarkets & MarketingNovo NordiskPharmaceuticalRegulationVictoza

Novo Nordisk files for EU approval of ultra-long-acting insulins Degludec and DegludecPlus


Danish insulin giant Novo Nordisk NVO: N) has made the first regulatory approval submissions, to the…

DegludecDiabetesEuropeNovo NordiskPharmaceuticalRegulation

Obesity drug market set to grow to $2.6 billion by 2020, says DR report


The obesity drug market will increase more than six-fold over the next decade, increasing from $420 million…

Arena PharmaceuticalsContraveLorqessMarkets & MarketingMetabolicsNovo NordiskOrexigen TherapeuticsPharmaceuticalQnexaVictozaVivus

High demand for monoclonal antibodies will drive therapeutic proteins market


The global therapeutic proteins market will grow at a moderate pace, with monoclonal antibodies considered…

AmgenBiotechnologyGlobalMarkets & MarketingNovo NordiskPharmaceuticalRoche

Data show Novo Nordisk’s ultra-long-acting insulin degludec can be flexibly dosed


Danish insulin giant Novo Nordisk’s (NVO: N) ultra-long-acting insulin degludec, an investigational…

DegludecDiabetesNovo NordiskPharmaceuticalResearch

Strong new data on Novo Nordisk’s Victoza and Lilly/Amylin’s Bydureon presented at EADS


A significantly higher proportion of patients reached the target for blood sugar control (HbA1c target…

AlkermesAmylinBydureonDiabetesEli LillyNovo NordiskPharmaceuticalResearchVictoza

Senior appointments at Novo Nordisk and Sucampo


The US unit of Danish insulin giant Novo Nordisk (NVO: N) has appointed Eddie Li, as vice president,…

ManagementNovo NordiskPharmaceuticalSucampo

Novo Nordisk extends free insulin and diabetes care program to India


Denmark’s Novo Nordisk (NVO: N), the world’s largest insulin maker, yesterday launched its…

Asia-PacificDiabetesMarkets & MarketingNovo NordiskPharmaceutical

Novo Nordisk first-half 2011 sales and profit leap


Danish insulin giant Novo Nordisk (NVO: N) posted first-half 2011 sales of 31.69 billion Danish kroner…

DiabetesFinancialNovo NordiskPharmaceuticalVictoza

European Commission and Australia OK Bristol-Myers Yervoy and Novo Nordisk’s FlexTouch


Following a recent positive recommendation from the European Medicine Agency’s advisory panel, Bristol-Myers…

Bristol-Myers SquibbDiabetesEuropeFlexTouchNovo NordiskOncologyPharmaceuticalRegulationYervoy

100 to 124 of 130 results

Company Spotlight



Back to top